BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Remsima SC wins approval for additional indications in Europe

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : June 29, 2020, 12:42 | Updated : June 29, 2020, 12:42
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Celltrion]


SEOUL -- Remsima SC, the subcutaneous injection of Remsima, a copy of Janssen Biotech's Remicade treating rheumatoid arthritis and Crohn's disease, has secured approval from a European watchdog for additional indications, opening the door for global use.

Remicade (Infliximab) biosimilar exist in the form of conventional intravenous injection. The target of Remsima SC is patients who are forced to move on to expensive secondary treatments due to resistance. Instead of an intravenous injection that takes more than two hours in hospital, patients can inject Remsima SC into the fat layer beneath the skin at home.

Celltrion, a leading biosimilar manufacturer in South Korea, said that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval for Remsima SC's indications covering Crohn's disease, ulcerative colitis, cataracts, psoriatic arthritis and psoriasis for adults. 

Remsima SC will be the first subcutaneous injection type to obtain all adult indications of Infliximab's intravenous injection type, Celltrion said, adding it would seek approval in 97 countries across the world within this year.

Celltrion said Remsima SC is expected to increase its global presence rapidly because medical staff's preference for infliximab prescription, a component of Remsima SC, is high in the field of inflammatory bowel disease. "Infliximab, the main ingredient of Ramsima SC, is considered the most preferred ingredient by specialists in inflammatory bowel disease, so a remarkable market share is expected in the future," an unnamed Celltrion official said in a statement. "

With Remsima SC, Celltrion has adopted an aggressive strategy to secure profitability and price penetration in competition with other subcutaneous-type products such as Adalimumab sold under the brand name of Humira, which is on the World Health Organization's list of essential medicines.



 

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Canada approves Celltrions subcutaneous injection for rheumatoid arthritis indication .
    Canada approves Celltrion's subcutaneous injection for rheum…
  • .Celltrion aims to become global pharmaceutical company through deal with Takeda.
    Celltrion aims to become global pharmaceutical company throu…
  • .Celltrion selected for state project to develop pen-type insulin biosimilar.
    Celltrion selected for state project to develop pen-type ins…
  • .[Coronavirus] Celltrion selected as priority negotiator in state project to develop treatment.
    [Coronavirus] Celltrion selected as priority negotiator in s…
  • .Bio firm Celltrion wins domestic approval to sell Remsima SC.
    Bio firm Celltrion wins domestic approval to sell Remsima SC

Real Time Photo News

  • .S. Korea to build state-run K-pop concert hall for unaffordable online performances .

    S. Korea to build state-run K-pop concert hall for unaffordable online performances

  • .BLACKPINK member Rosé to release solo album in March.

    BLACKPINK member Rosé to release solo album in March

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

  • .[FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene.

    [FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene

  • .CJ ENM aims to become major visual content producer thru partnership with Epic Games .

    CJ ENM aims to become major visual content producer thru partnership with Epic Games

Latest News

more+

  • Dongkuk Steel develops antiviral metal plates capable of killing COVID-19 virus in 30 minutes
  • Hyundai Glovis strengthens logistics partnership with China's Changjiu Group
  • Aramco partners with Hyundai shipbuilder to develop business model using hydrogen and ammonia
  • Hancom acquires drone technology startup Awesome Tech
  • S. Korea to build state-run K-pop concert hall for unaffordable online performances
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view